Eton Pharmaceuticals (ETON) closed at $56.46 on November 6, 2026, up 19.7% from the previous close, on volume of 1,214,129 shares (30-day average 517,798).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 28, 2026 | Strangle or Risk Reversal | 19-Feb-2740 P : 75 C | 282 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Eton Pharmaceuticals Earnings Call Highlights Record Growth
TipRanks (Fri, 6-Nov 7:29 PM ET)
Market Chameleon (Fri, 6-Nov 4:53 AM ET)
Eton Pharma jumps after Q3 beat and guidance hike
Seeking Alpha News (Fri, 6-Nov 9:04 AM ET)
At a glance: stocks gapping up premarket
Seeking Alpha News (Fri, 6-Nov 6:50 AM ET)
Eton Pharmaceuticals Reports Preliminary ET-700 Study Results
TipRanks (Thu, 5-Nov 5:11 PM ET)
Eton Pharmaceuticals Non-GAAP EPS of $0.50 beats by $0.13, revenue of $57.9M beats by $15.69M
Seeking Alpha News (Thu, 5-Nov 4:35 PM ET)
Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
Globe Newswire (Thu, 5-Nov 4:05 PM ET)
Globe Newswire (Thu, 5-Nov 4:01 PM ET)
Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London
Globe Newswire (Wed, 4-Nov 4:30 PM ET)
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Tue, 3-Nov 4:01 PM ET)
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
Eton Pharmaceuticals trades on the NASDAQ stock market under the symbol ETON.
As of November 6, 2026, ETON stock price climbed to $56.46 with 1,214,129 million shares trading.
ETON has a beta of -0.43, meaning it tends to be less sensitive to market movements. ETON has a correlation of 0.01 to the broad based SPY ETF.
ETON has a market cap of $1.61 billion. This is considered a Small Cap stock.
Last quarter Eton Pharmaceuticals reported $58 million in Revenue and $.50 earnings per share. This beat revenue expectation by $16 million and exceeded earnings estimates by $.14.
In the last 3 years, ETON traded as high as $66.37 and as low as $3.03.
The top ETF exchange traded funds that ETON belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
ETON has outperformed the market in the last year with a price return of +195.0% while the SPY ETF gained +10.8%. ETON has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +22.3% and +12.9%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
ETON support price is $45.54 and resistance is $48.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ETON shares will trade within this expected range on the day.
